Condition: Infertility (IVF Patients) · Sponsor: Granata Bio Corporation
The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| HRC Fertility | Encino, California, United States | Recruiting |
| Illume Fertility | Norwalk, Connecticut, United States | Recruiting |
| Reproductive Associates of Delaware CCRM | Newark, Delaware, United States | Not Yet Recruiting |
| IVF Florida Reproductive Associates | Margate, Florida, United States | Recruiting |
| Center for Reproductive Medicine | Winter Park, Florida, United States | Recruiting |
| Reproductive Biology Associates (RBA) | Atlanta, Georgia, United States | Recruiting |
| Fertility Institute of Hawaii | Honolulu, Hawaii, United States | Recruiting |
| Fertility Centers of Illinois | Chicago, Illinois, United States | Recruiting |
| Shady Grove Fertility - Rockville | Rockville, Maryland, United States | Recruiting |
| Boston IVF | Waltham, Massachusetts, United States | Recruiting |
| Reach Fertility | Charlotte, North Carolina, United States | Recruiting |
| Carolina Conceptions | Raleigh, North Carolina, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07216742